The fight over breast-cancer treatment with Roche's Avastin has come to a head: U.S. officials decided to revoke the drug's indication for breast cancer, and European Medicines Agency moved to restrict it for use with only one type of chemotherapy.
The decisions stand to cut more than $1 billion off Avastin's $6 billion in annual revenues, and they're sure to draw fire from folks who've been advocating for the drug.




In an unusual move, the Shin Bet security service has agreed to compensate Jamal al-Hindi, a member of the Popular Front for the Liberation of Palestine, for a partial disability that he says is due to having been tortured by Shin Bet agents 15 years ago. The amount of compensation remains secret by court order.
The problem is that the broad decline of the manufacturing sector that has been underway in this country for decades now may threaten not just the long-term health of the economy but also the living standards of all but the wealthiest Americans.
Yogurt’s good for you -- but apparently not quite as good as Dannon says it is. The yogurt maker will pay out $21 million to settle charges of deceptive advertising that it overstated health benefits for Activia and DanActive yogurt products, according to the Federal Trade Commission.
At last the United States is responding to Israeli Prime Minister Binyamin Netanyahu's refusal to freeze settlements and re-start negotiations with the Palestinians.





























